Cephalosporins and Beta-Lactams

Overview of Beta-Lactam Antibiotics

  • Beta-Lactams: A class of antibiotics that includes penicillins and cephalosporins.

    • Share structural features and mechanisms of action.

  • Cephalosporins: A large family of beta-lactam antibiotics categorized into five generations.

    • Generations: Reflect the evolving spectrum of activity against bacteria.

    • Each generation generally shows increased coverage for gram-negative bacteria and resistance to beta-lactamases.

    • Lower risk of cross-reactivity with penicillins than previously thought, but caution is still necessary.

Classification of Cephalosporins

  • First Generation:

    • Examples: Cefazolin, Cephalexin.

    • Primarily effective against gram-positive bacteria (e.g., staphylococci and streptococci).

    • Limited activity against gram-negative bacteria.

    • Mainly used for skin infections and surgical prophylaxis.

  • Second Generation:

    • Examples: Cefuroxime, Cefaclor, Cefoxitin.

    • Expanded coverage against gram-negative bacteria while retaining gram-positive effectiveness.

    • Indicated for respiratory infections, sinusitis, and intra-abdominal infections (especially those requiring anaerobic coverage).

  • Third Generation:

    • Examples: Ceftriaxone, Ceftazidime.

    • Broader gram-negative coverage suitable for serious systemic infections (e.g., community-acquired pneumonia, bacterial meningitis).

    • Ceftriaxone: Effective for gonorrhea; Ceftazidime: Notable for activity against Pseudomonas.

  • Fourth Generation:

    • Examples: Cefepime, Ceftolozane.

    • Broad spectrum covering both gram-positive and gram-negative bacteria, useful in hospital-acquired infections and immunocompromised patients.

    • Cefepime: Covers Pseudomonas; Ceftolozane: Often combined with tazobactam for complicated infections.

  • Advanced Generation:

    • Examples: Ceftaroline, Cefiderocol.

    • Effective against resistant infections, including MRSA.

    • Ceftaroline: Unique for binding PBP2A, specifically treats MRSA.

    • Cefiderocol: Designed for multidrug-resistant gram-negative infections, entering through iron transport channels.

Mechanism of Action

  • Cephalosporins kill bacteria by blocking cell wall synthesis:

    • Bind to penicillin-binding proteins (PBPs), disrupting the cross-linking of peptidoglycan chains.

    • Leads to weakened cell walls and bacterial lysis.

  • Exhibit time-dependent bactericidal activity: Minimum inhibitory concentration (MIC) needs to be maintained over time for effectiveness.

Clinical Applications

  • Broad range of infections treated, including:

    • Respiratory infections

    • Urinary tract infections

    • Skin infections

    • Intra-abdominal and surgical prophylaxis

    • Selection based on infection site and local resistance patterns.

Cephalosporin Formulations and Excretion

  • Available in both oral and parenteral formulations.

    • Oral medications (e.g., Cephalexin, Cefuroxime) generally well absorbed; bioavailability varies.

    • Renal excretion: Most cephalosporins require dose adjustments in renal impairment; Ceftriaxone is an exception due to dual elimination (kidneys and bile).

Side Effects and Considerations

  • Generally well tolerated, but side effects include:

    • Allergic reactions ranging from mild rash to anaphylaxis.

    • GI symptoms like nausea and diarrhea.

    • High doses can lead to neurotoxicity and seizures, particularly in renal impairment.

  • Ceftinir: Notable in pediatric patients for turning stool orange-red.

Resistance and Challenges

  • Resistance mechanisms include production of beta-lactamases and changes in penicillin-binding proteins.

  • Extended-spectrum beta-lactamases (ESBLs) can hydrolyze cephalosporins.

  • Carbapenem-resistant organisms are typically resistant to all cephalosporins, necessitating increased awareness of local resistance patterns.

Beta-Lactamase Inhibitors

  • Beta-lactamase inhibitors (e.g., Clavulanic acid, Sulbactam, Tazobactam, Avibactam) block bacteria's enzymes that degrade beta-lactams.

    • Often combined with penicillins or cephalosporins to enhance effectiveness against resistant organisms.

    • Not effective alone; their main role is to restore activity of beta-lactams.

Alternative Cell Wall Inhibitors

  • Other agents include:

    • Vancomycin: Glycopeptide, effective against gram-positive organisms; unable to penetrate gram-negative membranes.

    • Key in treating MRSA and enterococcal infections, administered IV (except for C. Diff).

    • Monitor for nephrotoxicity and red man syndrome during IV administration.

    • Monobactams (e.g., Aztreonam): Effective against aerobic gram-negative bacteria; useful for beta-lactam allergic patients.

    • Fosfomycin: Unique agent for uncomplicated urinary tract infections; single-dose effectiveness.

    • Polymyxins: Last-line agents for multidrug-resistant gram-negative pathogens, including nephrotoxic and neurotoxic risks.

Overview of Beta-Lactam Antibiotics

Beta-Lactams: A class of antibiotics that includes penicillins and cephalosporins. Share structural features and mechanisms of action.

Cephalosporins: A large family of beta-lactam antibiotics categorized into five generations. Generations reflect the evolving spectrum of activity against bacteria.

Each generation generally shows increased coverage for gram-negative bacteria and resistance to beta-lactamases.

Lower risk of cross-reactivity with penicillins than previously thought, but caution is still necessary.

Classification of Cephalosporins

  1. First Generation: Examples: Cefazolin, Cephalexin.

    • Primarily effective against gram-positive bacteria (e.g., staphylococci and streptococci).

    • Limited activity against gram-negative bacteria.

    • Mainly used for skin infections and surgical prophylaxis.

  2. Second Generation: Examples: Cefuroxime, Cefaclor, Cefoxitin.

    • Expanded coverage against gram-negative bacteria while retaining gram-positive effectiveness.

    • Indicated for respiratory infections, sinusitis, and intra-abdominal infections (especially those requiring anaerobic coverage).

  3. Third Generation: Examples: Ceftriaxone, Ceftazidime.

    • Broader gram-negative coverage suitable for serious systemic infections (e.g., community-acquired pneumonia, bacterial meningitis).

    • Ceftriaxone: Effective for gonorrhea; Ceftazidime: Notable for activity against Pseudomonas.

  4. Fourth Generation: Examples: Cefepime, Ceftolozane.

    • Broad spectrum covering both gram-positive and gram-negative bacteria, useful in hospital-acquired infections and immunocompromised patients.

    • Cefepime: Covers Pseudomonas; Ceftolozane: Often combined with tazobactam for complicated infections.

  5. Advanced Generation: Examples: Ceftaroline, Cefiderocol.

    • Effective against resistant infections, including MRSA.

    • Ceftaroline: Unique for binding PBP2A, specifically treats MRSA.

    • Cefiderocol: Designed for multidrug-resistant gram-negative infections, entering through iron transport channels.

Carbapenems

Carbapenems: A class of beta-lactam antibiotics that are highly resistant to beta-lactamases, making them effective against many resistant bacteria.
Examples: Imipenem, Meropenem, Ertapenem, Doripenem.

  • Broad-spectrum activity covering most gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa (except Ertapenem).

  • Indicated for severe infections such as intra-abdominal infections, pneumonia, and sepsis.

  • Administered parenterally; limited oral formulations available.

  • Side effects include gastrointestinal disturbances, seizures (especially with higher doses or renal impairment), and allergic reactions.

Mechanism of Action

Cephalosporins kill bacteria by blocking cell wall synthesis:
Bind to penicillin-binding proteins (PBPs), disrupting the cross-linking of peptidoglycan chains.

Leads to weakened cell walls and bacterial lysis.

Exhibit time-dependent bactericidal activity: Minimum inhibitory concentration (MIC) needs to be maintained over time for effectiveness.

Clinical Applications

Broad range of infections treated, including:

  • Respiratory infections

  • Urinary tract infections

  • Skin infections

  • Intra-abdominal and surgical prophylaxis
    Selection based on infection site and local resistance patterns.

Cephalosporin Formulations and Excretion

Available in both oral and parenteral formulations.
Oral medications (e.g., Cephalexin, Cefuroxime) generally well absorbed; bioavailability varies.

Renal excretion: Most cephalosporins require dose adjustments in renal impairment; Ceftriaxone is an exception due to dual elimination (kidneys and bile).

Side Effects and Considerations

Generally well tolerated, but side effects include:

  • Allergic reactions ranging from mild rash to anaphylaxis.

  • GI symptoms like nausea and diarrhea.

  • High doses can lead to neurotoxicity and seizures, particularly in renal impairment.

  • Ceftinir: Notable in pediatric patients for turning stool orange-red.

Resistance and Challenges

Resistance mechanisms include production of beta-lactamases and changes in penicillin-binding proteins.
Extended-spectrum beta-lactamases (ESBLs) can hydrolyze cephalosporins.
Carbapenem-resistant organisms are typically resistant to all cephalosporins, necessitating increased awareness of local resistance patterns.

Beta-Lactamase Inhibitors

Beta-lactamase inhibitors (e.g., Clavulanic acid, Sulbactam, Tazobactam, Avibactam) block bacteria's enzymes that degrade beta-lactams.
Often combined with penicillins or cephalosporins to enhance effectiveness against resistant organisms.

Not effective alone; their main role is to restore activity of beta-lactams.

Alternative Cell Wall Inhibitors

Other agents include:

  • Vancomycin: Glycopeptide, effective against gram-positive organisms; unable to penetrate gram-negative membranes.
    Key in treating MRSA and enterococcal infections, administered IV (except for C. Diff).
    Monitor for nephrotoxicity and red man syndrome during IV administration.

  • Monobactams (e.g., Aztreonam): Effective against aerobic gram-negative bacteria; useful for beta-lactam allergic patients.

  • Fosfomycin: Unique agent for uncomplicated urinary tract infections; single-dose effectiveness.

  • Polymyxins: Last-line agents for multidrug-resistant gram-negative pathogens, including nephrotoxic and neurotoxic risks.

Beta-lactamase inhibitors (e.g., Clavulanic acid, Sulbactam, Tazobactam, Avibactam) are designed to block enzymes produced by bacteria that degrade beta-lactam antibiotics. They are often combined with penicillins or cephalosporins to enhance effectiveness against resistant organisms. These inhibitors are not effective on their own; their primary role is to restore the activity of beta-lactams that would otherwise be rendered ineffective by the degradation process.

Key Points:

  • Clavulanic Acid: Often used in combination with amoxicillin (as Augmentin) to extend its spectrum against beta-lactamase-producing bacteria.

  • Sulbactam: Primarily combined with ampicillin to protect it from degradation, enhancing its efficacy for certain infections.

  • Tazobactam: Commonly paired with piperacillin, broadening its antibacterial activity against beta-lactamase-producing organisms.

  • Avibactam: A newer inhibitor that can restore the activity of cephalosporins against resistant Gram-negative infections that produce ESBLs.